

# Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

**Status:** RECRUITING

## Eligibility Criteria

**Age:** Not specified

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

### Inclusion Criteria:

\* Patients treated with OAV-101 with a genetically confirmed diagnosis of SMA regardless of the date of diagnosis. \* Appropriate consent/assent has been obtained for participation in the registry

---

### Exclusion Criteria:

- Currently enrolled in an interventional clinical trial involving an investigational medicinal product to treat SMA. Note: Patients who are participating in a Compassionate Use Program (CUP) for OAV-101 (Zolgensma) such as a Managed Access Program (MAP), an Expanded Access Program (EAP), Single Patient Investigational New Drug (IND) (SPI) or Named Patient Program (NPP) are eligible to enroll in the registry regardless of the date of a genetic or clinical diagnosis of SMA.

## Conditions & Interventions

### Interventions:

OTHER: Prospective observational registry, DRUG: Zolgensma

### Conditions:

Spinal Muscular Atrophy (SMA)

## More Information

**Contact(s):** Novartis Gene Therapies - [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

**Principal Investigator:** Johnson, Nicholas, E

**Phase:** N/A

**IRB**

**Number:** HM20015046

**System ID:** NCT04174157

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.